ID

43848

Description

Phase III, open, randomized study, in two centres, to demonstrate the equivalence of the 0, 12 month schedule to the 0, 6 month schedule with respect to the immunogenicity and to evaluate the safety and reactogenicity of GlaxoSmithKline Biologicals’ combined hepatitis A/ hepatitis B vaccine TWINRIX™ ADULT (720 EL. U. of hepatitis A antigen/ 20 μg of recombinant hepatitis B surface antigen) in healthy volunteers aged from 12 to 15 years inclusive. NCT00197171

Keywords

  1. 10/11/17 10/11/17 -
  2. 9/20/21 9/20/21 -
Copyright Holder

Glaxo Smith Kline

Uploaded on

September 20, 2021

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

GSK Study ID 100386 & 100387 Persistence of immune response to TWINRIX™ ADULT Long Term Follow up Year 6

Long Term Follow up Year 6

Long Term Follow up Visit 8
Description

Long Term Follow up Visit 8

Alias
UMLS CUI-1
C1517942
Center
Description

Study site identifier

Data type

text

Alias
UMLS CUI [1]
C2826692
Subject number
Description

Subject number

Data type

text

Alias
UMLS CUI [1]
C2348585
Treatment Number
Description

Treatment Number

Data type

text

Alias
UMLS CUI [1]
C1522541
Date of visit
Description

Date of visit

Data type

date

Alias
UMLS CUI [1]
C1320303
I certify that Informed Consent has been obtained prior to any study procedure.
Description

Informed consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
Informed Consent Date
Description

Informed Consent Date

Data type

date

Alias
UMLS CUI [1]
C2985782
Previous Studies
Description

Subject number will be the same as in the previous study.

Data type

integer

Alias
UMLS CUI [1]
C2242969
Demographics
Description

Demographics

Alias
UMLS CUI-1
C0011298
Date of birth
Description

Date of birth

Data type

date

Alias
UMLS CUI [1]
C0421451
Gender
Description

Gender

Data type

integer

Alias
UMLS CUI [1]
C0079399
Race
Description

Race

Data type

integer

Alias
UMLS CUI [1]
C0034510
Race, if other please specify
Description

Race

Data type

text

Alias
UMLS CUI [1]
C0034510
Has the subject had any serious adverse event since the end of the primary phase and before the start of this additional vaccination ?
Description

Serious adverse event

Data type

boolean

Alias
UMLS CUI [1]
C1519255
Specify number of SAEs
Description

Check SAE form(s) have been submitted to GSK Biologicals

Data type

integer

Alias
UMLS CUI [1]
C1519255
Laboratory Tests
Description

Laboratory Tests

Alias
UMLS CUI-1
C0022885
Has a blood sample been taken for testing anti-HAV and anti-HBs antibodies?
Description

Blood sample

Data type

boolean

Alias
UMLS CUI [1]
C0005834
Sample Collection Date
Description

Please complete only if different from visit date

Data type

date

Alias
UMLS CUI [1]
C1302413
Has the subject received a dose of monovalent or combined Hepatitis A or Hepatitis B vaccine?
Description

Vaccination since last visit

Data type

boolean

Alias
UMLS CUI [1,1]
C3543421
UMLS CUI [1,2]
C0589121
If yes, please specify vaccine
Description

Hepatitis vaccines

Data type

integer

Alias
UMLS CUI [1]
C3543421
Has the subject received a dose of Hepatitis A and/or Hepatitis B immunoglobulins within 6 months prior to bleeding?
Description

Hepatitis A and/or Hepatitis B immunoglobulins past 6 months

Data type

boolean

Alias
UMLS CUI [1,1]
C3652495
UMLS CUI [1,2]
C0062525
UMLS CUI [1,3]
C3828652
If yes, please specify
Description

Hepatitis A and/or Hepatitis B immunoglobulins

Data type

integer

Alias
UMLS CUI [1,1]
C3652495
UMLS CUI [1,2]
C0062525
Blood sample conclusion
Description

Blood sample conclusion

Alias
UMLS CUI-1
C0178913
UMLS CUI-2
C1254595
Has the patient become seronegative for anti-HAV antibodies
Description

Seronegativity anti-HAV antibodies

Data type

boolean

Alias
UMLS CUI [1,1]
C0521144
UMLS CUI [1,2]
C0062524
Has the patient lost seroprotective titres for anti-HBs antibodies
Description

seroprotective titres anti-HBs antibodies

Data type

boolean

Alias
UMLS CUI [1,1]
C0312543
UMLS CUI [1,2]
C0201478
If at least one answer is YES, is the subject than willing to receive an Additional Vaccination?
Description

Additional Vaccination consent

Data type

boolean

Alias
UMLS CUI [1,1]
C2713304
UMLS CUI [1,2]
C0021430
Investigator Signature
Description

Investigator Signature

Alias
UMLS CUI-1
C2346576
I confirm that I have reviewed the data in this Case Report Form for this subject. All information entered by myself or my colleagues is, to the best of my knowledge, complete and accurate, as of the date below.
Description

Confirmation

Data type

boolean

Alias
UMLS CUI [1]
C0750484
Investigator Signature
Description

Investigator Signature

Data type

text

Alias
UMLS CUI [1]
C2346576
Investigator name
Description

Investigator name

Data type

text

Alias
UMLS CUI [1]
C2826892
Date
Description

Date of completion

Data type

date

Alias
UMLS CUI [1]
C1549507

Similar models

Long Term Follow up Year 6

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Long Term Follow up Visit 8
C1517942 (UMLS CUI-1)
Study site identifier
Item
Center
text
C2826692 (UMLS CUI [1])
Subject number
Item
Subject number
text
C2348585 (UMLS CUI [1])
Treatment Number
Item
Treatment Number
text
C1522541 (UMLS CUI [1])
Date of visit
Item
Date of visit
date
C1320303 (UMLS CUI [1])
Informed consent
Item
I certify that Informed Consent has been obtained prior to any study procedure.
boolean
C0021430 (UMLS CUI [1])
Informed Consent Date
Item
Informed Consent Date
date
C2985782 (UMLS CUI [1])
Item
Previous Studies
integer
C2242969 (UMLS CUI [1])
Code List
Previous Studies
CL Item
100386 (HAB-158 EXT:082 Y5) (1)
Item Group
Demographics
C0011298 (UMLS CUI-1)
Date of birth
Item
Date of birth
date
C0421451 (UMLS CUI [1])
Item
Gender
integer
C0079399 (UMLS CUI [1])
Code List
Gender
CL Item
Male (1)
CL Item
Female (2)
Item
Race
integer
C0034510 (UMLS CUI [1])
Code List
Race
CL Item
Black (1)
CL Item
Arabic/North African (4)
CL Item
White/Caucasian (2)
CL Item
East & South East Asian (5)
CL Item
South Asian (6)
CL Item
Other,please specify (9)
Race
Item
Race, if other please specify
text
C0034510 (UMLS CUI [1])
Serious adverse event
Item
Has the subject had any serious adverse event since the end of the primary phase and before the start of this additional vaccination ?
boolean
C1519255 (UMLS CUI [1])
Serious adverse event
Item
Specify number of SAEs
integer
C1519255 (UMLS CUI [1])
Item Group
Laboratory Tests
C0022885 (UMLS CUI-1)
Blood sample
Item
Has a blood sample been taken for testing anti-HAV and anti-HBs antibodies?
boolean
C0005834 (UMLS CUI [1])
Sample Collection Date
Item
Sample Collection Date
date
C1302413 (UMLS CUI [1])
Vaccination since last visit
Item
Has the subject received a dose of monovalent or combined Hepatitis A or Hepatitis B vaccine?
boolean
C3543421 (UMLS CUI [1,1])
C0589121 (UMLS CUI [1,2])
Item
If yes, please specify vaccine
integer
C3543421 (UMLS CUI [1])
Code List
If yes, please specify vaccine
CL Item
Hepatitis A vaccine (1)
CL Item
Hepatitis B vaccine (2)
CL Item
Combined Hepatitis A and B vaccine (3)
Hepatitis A and/or Hepatitis B immunoglobulins past 6 months
Item
Has the subject received a dose of Hepatitis A and/or Hepatitis B immunoglobulins within 6 months prior to bleeding?
boolean
C3652495 (UMLS CUI [1,1])
C0062525 (UMLS CUI [1,2])
C3828652 (UMLS CUI [1,3])
Item
If yes, please specify
integer
C3652495 (UMLS CUI [1,1])
C0062525 (UMLS CUI [1,2])
Code List
If yes, please specify
CL Item
Hepatitis A immunoglobulins (1)
CL Item
Hepatitis B immunoglobulins (2)
Item Group
Blood sample conclusion
C0178913 (UMLS CUI-1)
C1254595 (UMLS CUI-2)
Seronegativity anti-HAV antibodies
Item
Has the patient become seronegative for anti-HAV antibodies
boolean
C0521144 (UMLS CUI [1,1])
C0062524 (UMLS CUI [1,2])
seroprotective titres anti-HBs antibodies
Item
Has the patient lost seroprotective titres for anti-HBs antibodies
boolean
C0312543 (UMLS CUI [1,1])
C0201478 (UMLS CUI [1,2])
Additional Vaccination consent
Item
If at least one answer is YES, is the subject than willing to receive an Additional Vaccination?
boolean
C2713304 (UMLS CUI [1,1])
C0021430 (UMLS CUI [1,2])
Item Group
Investigator Signature
C2346576 (UMLS CUI-1)
Confirmation
Item
I confirm that I have reviewed the data in this Case Report Form for this subject. All information entered by myself or my colleagues is, to the best of my knowledge, complete and accurate, as of the date below.
boolean
C0750484 (UMLS CUI [1])
Investigator Signature
Item
Investigator Signature
text
C2346576 (UMLS CUI [1])
Investigator name
Item
Investigator name
text
C2826892 (UMLS CUI [1])
Date of completion
Item
Date
date
C1549507 (UMLS CUI [1])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial